BURNABY, British Columbia & PETACH TIKVA, Israël – (BUSINESS WIRE) – ARTMS Inc. (ARTMS) en Isotopia Molecular Imaging (Isotopia) zijn verheugd de succesvolle radiolabeling aan te kondigen van Isotopia’s kit voor prostaatkankerbeeldvorming, PSMA-11, met meer dan 2 Ci van cyclotron-geproduceerd Gallium-68 (68Ga) met behulp van ARTMS ‘gepatenteerde Quantum Irradiation System™ (QIS™) solide doelsysteem.
Dit persbericht bevat multimedia. Bekijk de volledige release hier: https://www.businesswire.com/news/home/20210119005044/en/
De speciaal ontworpen Prostate-Specific Membrane Antigen (PSMA) -kit voor de bereiding van 68Ga-PSMA-11 (een radiofarmaceuticum gericht op PSMA voor de beeldvorming van prostaatkanker met behulp van Positron Emission Tomography (PET)) werd radioactief gelabeld met cyclotron met hoge activiteit en produceerde 68Ga na bestraling tijden van minder dan twee uur. De Isotopia-kit werd radioactief gelabeld met tussen 500 mCi en iets meer dan 2900 mCi 68Ga na meerdere succesvolle 68Ga-productieruns met gebruikmaking van de QIS™ en de krachtige 68Zn-doelen van ARTMS. Het resulterende product vertoonde een stabiliteit van 6 uur en een radiochemische zuiverheid, die aan alle wettelijke normen voldeed of deze overtrof. Cyclotron geproduceerd 68Ga in combinatie met een kitoplossing geeft radiofarmaca vrijwel onbeperkte toegang tot dit diagnostische product en een kosteneffectieve oplossing.
ARTMS and Isotopia Molecular Imaging Announce Successful Multi-Curie Labeling of PSMA-11 With Cyclotron Produced 68Ga Utilizing the QUANTM Irradiation System™ and Solid Targets
BURNABY, British Columbia & PETACH TIKVA, Israel–(BUSINESS WIRE)– ARTMS Inc. (ARTMS) and Isotopia Molecular Imaging (Isotopia) are pleased to announce the successful radiolabeling of Isotopia’s prostate cancer imaging kit product, PSMA-11, with over 2 Ci of cyclotron-produced Gallium-68 (68Ga) using ARTMS’ proprietary Quantum Irradiation System™ (QIS™) solid target system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005044/en/
The specially designed Prostate-Specific Membrane Antigen (PSMA) kit for the preparation of 68Ga-PSMA-11 (a radiopharmaceutical targeting PSMA for the imaging of prostate cancer using Positron Emission Tomography (PET)) was radiolabeled with high activity cyclotron produced 68Ga following irradiation times of less than two hours. The Isotopia kit was radiolabeled with between 500 mCi and just over 2900 mCi of 68Ga following multiple successful 68Ga production runs utilizing the QIS™ and ARTMS’ high performance 68Zn solid targets. The resultant product demonstrated 6-hour stability and radiochemical purity, which met or exceeded all regulatory standards. Cyclotron produced 68Ga combined with a kit solution will give radiopharmacies near unlimited access to this diagnostic product and a cost effective solution.
“The demand for 68Ga radiolabeled products will soon exceed the supply coming from 68Ge/68Ga generators. ARTMS’ QUANTM Irradiation System™ (QIS™) allows for the high activity and high quality 68Ga production the Molecular Imaging community requires to properly serve their patients. The QIS™’ multiple-curie per hour 68Ga production is one of the few true game changers I have seen during my career in Nuclear Medicine. We are very excited to bring on-demand 68Ga doses to clinicians and patients in collaboration with our partners,” says Charles S. Conroy, Chief Executive Officer of ARTMS.
“Isotopia is focused on developing diagnostic and therapeutic tools that best serve our patients. We see 68Ga as a better diagnostic tool to pair with Lu177 treatments. Isotopia’s high activity PSMA “kit” is a major step forward in how the global imaging community diagnoses prostate cancer. Multi-dose vial preparation will allow pharmacies to provide unit doses and allow clinicians to image patients with little to no restrictions. In addition, a 5 minute preparation and more than 95% radiochemical purity will enhance efficiency and save the radiopharmacies time and money. We aim to keep introducing to the market kit-based solutions for 50 and 100mCi Generators, cyclotron produced 68Ga, and Lu177 labeling,” says Dr. Eli Shalom, CEO of Isotopia Molecular Imaging.
ARTMS recently announced the approval for its cyclotron produced 99mTc product by Health Canada. ARTMS will continue the development of cyclotron-based products including 68Ga with a focus on optimizing production potential and satisfying regulatory requirements for use in radiopharmaceutical kits.
About Prostate Cancer
Prostate cancer is the fourth most common cancer worldwide. In 2018, 1.3 million men were diagnosed with prostate cancer for the first time. Despite advances in treatments, prostate cancer still accounts for a significant number of deaths. In 2018, more than 365,000 men died from the disease. Rates of diagnosis are increasing, and the highest levels of prostate cancer are found in the US, Europe, Australia, and New Zealand.
Based in Vancouver, British Columbia, Canada, ARTMS Inc. is the global leader in the development of novel technologies and products which enable the high-quality and high-yield production of the world’s most-used diagnostic imaging isotopes. ARTMS’ flagship product, the QUANTM Irradiation System™ (QIS™), enables decentralized, cost-effective, large-scale production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium-99m (99mTc) and copper-64 (64Cu) using pharmaceutical distributor and hospital-based medical cyclotrons, empowering users to control their supply chain. ARTMS commercializes these award-winning and proprietary Canadian inventions on a global basis and has the prospect of revolutionizing the nuclear medicine industry.
Isotopia Molecular Imaging Ltd. is a collaboration between The Metrontario Group and some of Israel’s leading scientists in the field of radiopharmaceuticals. The Isotopia development team is a multidisciplinary team consisting of nuclear pharmacists, radiochemists, nuclear engineers, and physicists. The experienced Isotopia team, together with its radio-nuclear pharmacy, cyclotron facility, 177Lu production site and sterile manufacturing, are a well-established platform for development. Isotopia creates collaborations between the scientific and medical community to further develop and experiment with new markers for imaging applications and molecular therapy.
For more information on Isotopia, please visit www.isotopia.co.il.
Charles S. Conroy R.Ph, MBA
Chief Executive Officer
Chief Commercial Officer
Dr. Eli Shalom, PhD
Isotopia Molecular Imaging Limited
Chief Executive Officer
Isotopia Molecular Imaging Limited
Director of Business Development